{"id":379201,"date":"2020-11-12T01:36:22","date_gmt":"2020-11-12T06:36:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379201"},"modified":"2020-11-12T01:36:22","modified_gmt":"2020-11-12T06:36:22","slug":"interim-report-q3-2020-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/","title":{"rendered":"Interim Report Q3, 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Expansion of pipeline and positive phase 3 topline data<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">STOCKHOLM<\/span>, <span class=\"xn-chron\">Nov. 12, 2020<\/span> \/PRNewswire\/ &#8212; &#8220;On <span class=\"xn-chron\">August 13<\/span><sup>th<\/sup>, we announced a \u20ac19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in <span class=\"xn-location\">France<\/span>. We are very excited about this acquisition, which complements our existing and long-standing focus on inflammatory disease. This provides us with a platform with anti-fibrotic and anti-inflammatory compounds, with which we believe can continue to address unmet medical need in orphan diseases and bring solutions to patients across many different therapeutic areas. We believe that we have significant opportunities to leverage this platform to the benefit of patients suffering from fibrotic diseases. We believe that the late stage development, CMC and regulatory expertise which exists in Calliditas can significantly support and enhance the important fundamentals put in place by Genkyotex. We are confident that this will be value driving, for all the company&#8217;s stakeholders, over the near and medium term.<\/p>\n<p>After the close of the quarter, on <span class=\"xn-chron\">November 8<\/span><sup>th<\/sup>, we reported positive topline results from Part A of our pivotal Phase 3 trial, NefIgArd. The strong data set confirms the results seen in the successful Phase <span class=\"xn-money\">2b<\/span> trial and provides further support for locally treating IgAN at the source, offering patients hope of disease modification. We will now assemble the regulatory file and submit for accelerated approval with the FDA and conditional approval with EMA, which is planned for Q1 and H1 respectively next year.&#8221;<\/p>\n<p>\n        <i>Ren\u00e9e Aguiar-Lucander, CEO<\/i>\n      <\/p>\n<p>\n        <b>Summary of Q3 2020<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-chron\">July 1 &#8211; September 30, 2020<\/span>\n      <\/p>\n<ul type=\"disc\">\n<li>No net sales were recognized for the three months ended <span class=\"xn-chron\">September 30, 2020<\/span> and 2019, respectively. <\/li>\n<li>Operating loss amounted to <span class=\"xn-money\">SEK 104.9 million<\/span> and <span class=\"xn-money\">SEK 52.6 million<\/span> for the three months ended <span class=\"xn-chron\">September 30, 2020<\/span> and 2019, respectively. <\/li>\n<li>Loss before income tax amounted to <span class=\"xn-money\">SEK 137.9 million<\/span> and <span class=\"xn-money\">SEK 50.1 million<\/span> for the three months ended <span class=\"xn-chron\">September 30, 2020<\/span> and 2019, respectively. <\/li>\n<li>Loss per share before and after dilution amounted to <span class=\"xn-money\">SEK 2.77<\/span> and <span class=\"xn-money\">SEK 1.30<\/span>, for the three months ended <span class=\"xn-chron\">September 30, 2020<\/span> and 2019, respectively. <\/li>\n<li>Cash amounted to <span class=\"xn-money\">SEK 1,396.9 million<\/span> and <span class=\"xn-money\">SEK 805.1 million<\/span> as of <span class=\"xn-chron\">September 30, 2020<\/span> and 2019, respectively.<\/li>\n<\/ul>\n<p>\n        <b>Significant events during Q3 2020, in summary<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">July 2020<\/span>, Calliditas announced the exercise of the partial over-allotment option from the IPO on The Nasdaq Global Select Market. Calliditas was thereby provided with additional gross proceeds of approximately <span class=\"xn-money\">USD 6.9 million<\/span> (approximately <span class=\"xn-money\">SEK 63 million<\/span>) before deduction of issuance costs. <\/li>\n<li>In <span class=\"xn-chron\">August 2020<\/span>, Calliditas announced it has reached an agreement to acquire a controlling interest in Genkyotex SA, a leader in NOX inhibition therapies.<\/li>\n<\/ul>\n<p>\n        <b>Significant events after the end of reporting period, in summary<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">November 2020<\/span>, Calliditas acquired a controlling interest in Genkyotex SA representing 62,7%. <\/li>\n<li>In <span class=\"xn-chron\">November 2020<\/span>, Calliditas announced positive topline results from Part A from the pivotal Phase 3 NefIgArd trial.<\/li>\n<\/ul>\n<p>\n        <b>Investor Presentation <span class=\"xn-chron\">November 12<\/span>, <span class=\"xn-chron\">14:30 CET<\/span><\/b>\n      <\/p>\n<p>Audio cast with teleconference, Q3 2020, <span class=\"xn-chron\">November 12, 2020<\/span>, 14:30 (<span class=\"xn-location\">Europe<\/span>\/<span class=\"xn-location\">Stockholm<\/span>)<\/p>\n<p>Webcast: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979724-1&amp;h=2562387122&amp;u=https%3A%2F%2Ftv.streamfabriken.com%2Fcalliditas-therapeutics-q3-2020&amp;a=https%3A%2F%2Ftv.streamfabriken.com%2Fcalliditas-therapeutics-q3-2020\" rel=\"nofollow noopener noreferrer\">https:\/\/tv.streamfabriken.com\/calliditas-therapeutics-q3-2020<\/a> \u00a0<\/p>\n<p>Teleconference: SE: +46856642707 UK: +443333009034 US: +18332498405<\/p>\n<p>\n        <b>Financial calendar<\/b>\n      <\/p>\n<p>Year-end report for the period <span class=\"xn-chron\">January 1 &#8211; December 31<\/span>, 2020\u00a0 <span class=\"xn-chron\">February 18, 2021<\/span><\/p>\n<p>Interim report for the period <span class=\"xn-chron\">January 1 &#8211; March 31<\/span>, 2021\u00a0 <span class=\"xn-chron\">May 13, 2021<\/span><\/p>\n<p>Interim report for the period <span class=\"xn-chron\">January 1 &#8211; June 30<\/span>, 2021\u00a0 <span class=\"xn-chron\">August 19, 2021<\/span><\/p>\n<p>Interim report for the period <span class=\"xn-chron\">January 1 &#8211; September 30<\/span>, 2021\u00a0 <span class=\"xn-chron\">November 18, 2021<\/span><\/p>\n<p>\n        <b>For further information, please contact<\/b>: <\/p>\n<p>Ren\u00e9e Aguiar-Lucander, CEO at Calliditas <br \/>Email: <a target=\"_blank\" href=\"mailto:renee.lucander@calliditas.com\" rel=\"nofollow noopener noreferrer\">renee.lucander@calliditas.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Mikael Widell<\/span>, Investor Relations <br \/>Email: <a target=\"_blank\" href=\"mailto:mikael.widell@calliditas.com\" rel=\"nofollow noopener noreferrer\">mikael.widell@calliditas.com<\/a><br \/>Telephone: +46 703 11 99 60<\/p>\n<p>\n        <i>The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at <span class=\"xn-chron\">07:00 CET<\/span> on <span class=\"xn-chron\">November 12, 2020<\/span>.<\/i>\n      <\/p>\n<p>\n        <b>About Calliditas Therapeutics<\/b>\n      <\/p>\n<p>Calliditas Therapeutics is a specialty pharmaceutical company based in <span class=\"xn-location\">Stockholm, Sweden<\/span>. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique two-step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979724-1&amp;h=3113062095&amp;u=http%3A%2F%2Fwww.calliditas.com%2F&amp;a=www.calliditas.com\" rel=\"nofollow noopener noreferrer\">www.calliditas.com<\/a> \u00a0for further information.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Calliditas&#8217; strategy, business plans and focus. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas&#8221; business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in the section entitled &#8220;Risk Factors&#8221; Calliditas&#8217; reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas&#8221; views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979724-1&amp;h=3461432167&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979724-1&amp;h=1848104201&amp;u=https%3A%2F%2Fnews.cision.com%2Fcalliditas-therapeutics%2Fr%2Finterim-report-q3--2020%2Cc3235709&amp;a=https%3A%2F%2Fnews.cision.com%2Fcalliditas-therapeutics%2Fr%2Finterim-report-q3--2020%2Cc3235709\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/calliditas-therapeutics\/r\/interim-report-q3&#8211;2020,c3235709<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979724-1&amp;h=2344280667&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F16574%2F3235709%2F1334046.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F16574%2F3235709%2F1334046.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/16574\/3235709\/1334046.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Release<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979724-1&amp;h=291853520&amp;u=https%3A%2F%2Fmb.cision.com%2FPublic%2F16574%2F3235709%2F95e9d8325bc477ed.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FPublic%2F16574%2F3235709%2F95e9d8325bc477ed.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Public\/16574\/3235709\/95e9d8325bc477ed.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Press release Q3 2020 ENG<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/interim-report-q3-2020-301171586.html\">http:\/\/www.prnewswire.com\/news-releases\/interim-report-q3-2020-301171586.html<\/a><\/p>\n<p>SOURCE  Calliditas Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO89623&amp;Transmission_Id=202011120132PR_NEWS_USPR_____IO89623&amp;DateId=20201112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Expansion of pipeline and positive phase 3 topline data PR Newswire STOCKHOLM, Nov. 12, 2020 \/PRNewswire\/ &#8212; &#8220;On August 13th, we announced a \u20ac19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in France. We are very excited about this acquisition, which complements our existing and long-standing focus on inflammatory disease. This provides us with a platform with anti-fibrotic and anti-inflammatory compounds, with which we believe can continue to address unmet medical need in orphan diseases and bring solutions to patients across many different therapeutic areas. We believe that we have significant opportunities to leverage this platform to the benefit of patients suffering from fibrotic diseases. We believe that the late stage development, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Interim Report Q3, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379201","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interim Report Q3, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim Report Q3, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Expansion of pipeline and positive phase 3 topline data PR Newswire STOCKHOLM, Nov. 12, 2020 \/PRNewswire\/ &#8212; &#8220;On August 13th, we announced a \u20ac19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in France. We are very excited about this acquisition, which complements our existing and long-standing focus on inflammatory disease. This provides us with a platform with anti-fibrotic and anti-inflammatory compounds, with which we believe can continue to address unmet medical need in orphan diseases and bring solutions to patients across many different therapeutic areas. We believe that we have significant opportunities to leverage this platform to the benefit of patients suffering from fibrotic diseases. We believe that the late stage development, &hellip; Continue reading &quot;Interim Report Q3, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T06:36:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Interim Report Q3, 2020\",\"datePublished\":\"2020-11-12T06:36:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/\"},\"wordCount\":1040,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO89623&amp;sd=2020-11-12\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/\",\"name\":\"Interim Report Q3, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO89623&amp;sd=2020-11-12\",\"datePublished\":\"2020-11-12T06:36:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO89623&amp;sd=2020-11-12\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO89623&amp;sd=2020-11-12\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/interim-report-q3-2020-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim Report Q3, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim Report Q3, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/","og_locale":"en_US","og_type":"article","og_title":"Interim Report Q3, 2020 - Market Newsdesk","og_description":"Expansion of pipeline and positive phase 3 topline data PR Newswire STOCKHOLM, Nov. 12, 2020 \/PRNewswire\/ &#8212; &#8220;On August 13th, we announced a \u20ac19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in France. We are very excited about this acquisition, which complements our existing and long-standing focus on inflammatory disease. This provides us with a platform with anti-fibrotic and anti-inflammatory compounds, with which we believe can continue to address unmet medical need in orphan diseases and bring solutions to patients across many different therapeutic areas. We believe that we have significant opportunities to leverage this platform to the benefit of patients suffering from fibrotic diseases. We believe that the late stage development, &hellip; Continue reading \"Interim Report Q3, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T06:36:22+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Interim Report Q3, 2020","datePublished":"2020-11-12T06:36:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/"},"wordCount":1040,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/","name":"Interim Report Q3, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12","datePublished":"2020-11-12T06:36:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO89623&amp;sd=2020-11-12"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/interim-report-q3-2020-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Interim Report Q3, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379201"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379201\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}